Literature DB >> 12163896

Risk-of-malignancy index in preoperative evaluation of clinically restricted ovarian cancer.

José Carlos Campos Torres1, Sophie Françoise Mauricette Derchain, Aníbal Faundes, Renata Clementino Gontijo, Edson Zangiacomi Martinez, Liliana Aparecida Luccide Angelo Andrade.   

Abstract

CONTEXT: There is no adequate preoperative method for differentiating between benign and malignant pelvic masses. Evaluations of CA 125 serum levels, ultrasonography findings and menstrual state have been tested in isolation as diagnostic methods. The evaluation of these three methods in association with each other could improve diagnostic performance.
OBJECTIVE: To evaluate the risk-of-malignancy index by combining serum CA 125 levels, ultrasound score and menopausal status in preoperative diagnoses for women with pelvic masses clinically restricted to the ovaries and without clear evidence of malignancy.
DESIGN: Cross-sectional study.
SETTING: Centro de Atenção Integral à Saúde da Mulher, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil. PARTICIPANTS: 158 women admitted between January 1996 and March 1998 for surgical exploration of pelvic masses. PROCEDURES: The risk-of-malignancy index was calculated as US x M x CA 125, performed preoperatively. Ultrasound findings were classified according to the shape, size, multiplicity, presence of wall expansion involvement or ascites, using a score system (US). Menopausal status was considered as 1 for premenopausal and 3 for postmenopausal (M), and CA 125 serum levels were considered in absolute values. STATISTICAL ANALYSIS: Most relevant variables were included in a logistic multiple regression model, fitted using the ultrasound score, the serum CA 125 level and the menopausal status. The model was used for evaluating the performance of each individual predictor in determining the malignancy of these tumors and identifying the risk-of-malignancy index.
RESULTS: The best individual performance was found in CA 125 levels (sensitivity of 78%, specificity of 75%), followed by ultrasound score (sensitivity of 75%, specificity of 73%) and menopausal status (sensitivity of 73%, specificity of 69%). The performance obtained for the risk-of-malignancy index at the cut-off point of 150 was a sensitivity and specificity of 79%. The area under the ROC curve for the risk-of-malignancy index was 0.90, which was greater than the area for CA 125 levels (0.83) or ultrasound score (0.79).
CONCLUSION: The risk-of-malignancy index using ultrasound morphological score, serum CA 125 levels and menopausal status might be of value in the preoperative assessment of ovarian carcinomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163896     DOI: 10.1590/s1516-31802002000300003

Source DB:  PubMed          Journal:  Sao Paulo Med J        ISSN: 1516-3180            Impact factor:   1.044


  9 in total

1.  Management of a suspicious adnexal mass: a clinical practice guideline.

Authors:  J E Dodge; A L Covens; C Lacchetti; L M Elit; T Le; M Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

2.  Pediatric risk of malignancy index for preoperative evaluation of childhood ovarian tumors.

Authors:  Amos Hong Pheng Loh; Chiou Li Ong; Shu Lin Lam; Joyce Horng Yiing Chua; Chan Hon Chui
Journal:  Pediatr Surg Int       Date:  2011-12-08       Impact factor: 1.827

3.  Risk of malignancy index as an evaluation of preoperative pelvic mass.

Authors:  Zinatossadat Bouzari; Shahla Yazdani; Ziba Shirkhani Kelagar; Narges Abbaszadeh
Journal:  Caspian J Intern Med       Date:  2011

4.  Is Risk Malignancy Index a Useful Tool for Predicting Malignant Ovarian Masses in Developing Countries?

Authors:  Aliya B Aziz; Nida Najmi
Journal:  Obstet Gynecol Int       Date:  2015-06-21

5.  Criteria for selection of laparoscopy for women with adnexal mass.

Authors:  Amilcar Barreta; Luis Felipe Sallum; Luis Otávio Sarian; Joana Fróes Bragança Bastos; Sophie Derchain
Journal:  JSLS       Date:  2014 Jul-Sep       Impact factor: 2.172

6.  A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass.

Authors:  Santosh Kumar Dora; Atal Bihari Dandapat; Benudhar Pande; Jatindra Prasad Hota
Journal:  J Ovarian Res       Date:  2017-08-14       Impact factor: 4.234

7.  Discovery of specific metastasis-related N-glycan alterations in epithelial ovarian cancer based on quantitative glycomics.

Authors:  Xingwang Zhang; Yisheng Wang; Yifan Qian; Xin Wu; Zejian Zhang; Xijun Liu; Ran Zhao; Lei Zhou; Yuanyuan Ruan; Jiejie Xu; Haiou Liu; Shifang Ren; Congjian Xu; Jianxin Gu
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

Review 8.  Current clinical application of serum biomarkers to detect ovarian cancer.

Authors:  Marek Nowak; Łukasz Janas; Grzegorz Stachowiak; Tomasz Stetkiewicz; Jacek R Wilczyński
Journal:  Prz Menopauzalny       Date:  2015-11-27

Review 9.  Current clinical application of serum biomarkers to detect and monitor ovarian cancer - update.

Authors:  Łukasz Janas
Journal:  Prz Menopauzalny       Date:  2022-01-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.